# A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

> **NCT05338619** · PHASE2 · UNKNOWN · sponsor: **Sung Yong Lee** · enrollment: 77 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage III
- EGFR Positive Non-small Cell Lung Cancer
- Non-squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Lazertinib

## Key facts

- **NCT ID:** NCT05338619
- **Lead sponsor:** Sung Yong Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2026-03-02
- **Final completion:** 2026-03-02
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2023-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338619, "A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05338619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*